3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 2
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
2
Conditions
Carcinoma, Non-Small-Cell Lung
14
Multiple Myeloma
6
Lung Neoplasms
6
Lymphoma
5
Lymphoma, Large-Cell, Anaplastic
3
Hematologic Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Rhabdomyosarcoma, Alveolar
1
Relapsed Pediatric Solid Tumor
1
Rectal Neoplasms
1
Rare Tumor
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neurofibromatosis 2
1
Interventions
Oxaliplatin
67
Capecitabine
60
Fluorouracil
58
Bevacizumab
54
Gemcitabine
51
Paclitaxel
50
Leucovorin
50
Irinotecan
40
Docetaxel
39
Carboplatin
39
Cisplatin
38
pembrolizumab
37
Nivolumab
37
Cetuximab
35
Sunitinib
25
Trastuzumab
24
Radiosurgery
24
Radiotherapy
21
Doxorubicin
21
Cyclophosphamide
21
Panitumumab
20
Drug Therapy
19
Pemetrexed
18
Everolimus
18
Sorafenib
17
Interleukin-2
16
Fulvestrant
16
Albumin-Bound Paclitaxel
16
atezolizumab
15
Erlotinib Hydrochloride
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm Metastasis
×
Crizotinib
×
Clear all
NCT02034981
2024-02-28
AcSé
UNICANCER
Phase 2
Completed
246 enrolled
NCT02142036
2019-03-13
MetAction
Oslo University Hospital
Phase 2
Completed
50 enrolled